Mersana Therapeutics, Inc. (MRSN) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
840 Memorial Drive
Cambridge, MA 02139
United States of America (the)
Phone
617 498 0020
Website
Sector
Healthcare
Industry
Biotechnology
Employees
102
First IPO Date
June 28, 2017
| Name | Title | Pay | Year Born |
| Martin H. Huber | President, Chief Executive Officer & Director | 962,075 | 1960 |
| Alejandra Veronica Carvajal | Senior Vice President, Secretary & Chief Legal Officer | 623,525 | 1974 |
| Mohan Bala | Senior Vice President & Chief Development Officer | 643,850 | 1965 |
| Timothy Lowinger | Senior Vice President and Chief Science & Technology Officer | 664,175 | 1964 |
| Brian C. DeSchuytner | Senior Vice President, Chief Financial Officer & Chief Operating Officer | 684,500 | 1978 |
| Marc Damelin | Exe. Director and Head of Biology, Oncology, Antibody-Drug Conjugate ADC Discovery & Develop. | 0 | N/A |
| Chuck Miller | Senior Vice President of Regulatory Affairs | 0 | N/A |
| Mikhail Papisov | Co-Founder | 0 | N/A |
| Ashish Mandelia | Vice President & Chief Accounting Officer | 0 | 1975 |
| Jason Fredette | Senior Vice President of Investor Relations & Corporate Communications | 0 | N/A |
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to pioneering novel antibody-drug conjugates (ADCs) for cancer patients with pressing unmet medical needs. Their flagship product candidate, XMT-1592, a Dolasynthen ADC engineered to target NaPi2b-expressing tumor cells, is presently undergoing Phase I clinical evaluation for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company's development pipeline also includes XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate, and XMT-2056, an Immunosynthen development candidate. Additionally, Mersana maintains strategic research and development collaborations with Merck KGaA and Asana BioSciences, LLC for the creation of ADC product candidates, leveraging its Fleximer technology. Incorporated in 2001, the company initially operated as Nanopharma Corp. before rebranding as Mersana Therapeutics, Inc. in November 2005, and is headquartered in Cambridge, Massachusetts.